ClinicalTrials.gg
RecruitingNCT07662044Eluminate-1Updated Aug 31, 2026

A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Alone or in Combination With Dapagliflozin Compared With Placebo in Adults With Type 2 Diabetes Mellitus

A Phase 3 interventional study of Elecoglipron and Dapagliflozin in Type 2 Diabetes Mellitus, sponsored by AstraZeneca. Recruiting at 149 sites in 13 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-31.

Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started Jul 2026; still recruiting 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
800
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 18 studies testing elecoglipron in Diabetes Mellitus, Type 2 — 6 open to participants now, 7 under way, 6 of them phase 3. elecoglipron · Diabetes Mellitus, Type 2.

Planned enrollment
4th of 18
800 · median 57
Started
2026
with 8 others
Phase 3
6 of 18
6 open now
Registered
13th of 18
by date
Lead sponsor
14 of 18
AstraZeneca

Among the 18 studies testing elecoglipron in Diabetes Mellitus, Type 2, this one is the 4th largest by planned enrollment, is one of 9 that started in 2026, is one of 6 in phase 3, and was the 13th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

6 of the 18 studies testing elecoglipron in Diabetes Mellitus, Type 2 are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

About elecoglipron

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies testing elecoglipron in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the efficacy, safety, and tolerability of elecoglipron alone or in combination with dapagliflozin compared with placebo in adults with type 2 diabetes mellitus (T2DM) inadequately managed with lifestyle management alone or treated with other background glucose-lowering medication.

03

Conditions studied

  • Type 2 Diabetes Mellitus
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosed with Type 2 Diabetes Mellitus (T2DM) for at least 90 days prior to screening
  • T2DM inadequately managed with lifestyle management alone or on stable treatment with other background glucose-lowering medication
  • value of ≥ 7% to ≤ 10.5% (53 to 91.3 mmol/mol)
  • (BMI) of ≥ 23 kg/m2 at screening
  • Stable body weight (self-reported or documented) for 90 days prior to screening

Exclusion criteria

Exclusion Criteria:

  • Type 1 diabetes, secondary forms of diabetes (including congenital forms), or history of ketoacidosis or hyperosmolar coma
  • Currently receiving or anticipated to receive, therapeutic intervention for diabetic retinopathy and/or macular edema
  • Have had more than one episode of severe hypoglycemia within 180 days prior to screening or has a history of hypoglycemia unawareness or poor recognition of hypoglycemic symptoms
  • condition affecting the upper GI tract or chronic use of any medication that affects gastric motility or gastric emptying
  • History of acute or chronic pancreatitis
  • Severe congestive heart failure ( IV)
  • History/family history of medullary thyroid cancer or multiple endocrine neoplasia type 2
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
800 participants (estimated)

Study arms

  • Experimental
    Elecoglipron dose level 1 + dapagliflozin-matched placebo

    Participants will receive elecoglipron at dose level 1 and dapagliflozin-matched placebo, administered orally once daily.

    Drug: Elecoglipron · Drug: Dapagliflozin-matched placebo

  • Experimental
    Elecoglipron dose level 2 + dapagliflozin-matched placebo

    Participants will receive elecoglipron at dose level 2 and dapagliflozin-matched placebo, administered orally once daily.

    Drug: Elecoglipron · Drug: Dapagliflozin-matched placebo

  • Experimental
    Elecoglipron (one of the studied dose levels) + dapagliflozin

    Participants will receive elecoglipron at one of the study dose levels in combination with dapagliflozin, administered orally once daily.

    Drug: Elecoglipron · Drug: Dapagliflozin

  • Placebo comparator
    Elecoglipron-matched placebo + dapagliflozin-matched placebo

    Participants will receive elecoglipron-matched placebo and dapagliflozin-matched placebo, administered orally once daily.

    Drug: Elecoglipron-matched placebo · Drug: Dapagliflozin-matched placebo

Interventions

  • Elecoglipron is administered orally once daily.

  • Dapagliflozin administered orally once daily.

  • DrugElecoglipron-matched placebo

    A placebo matching elecoglipron, administered orally once daily.

  • DrugDapagliflozin-matched placebo

    A placebo matching dapagliflozin, administered orally once daily.

06

What researchers measure

Primary outcomes

  1. Change from baseline in Hemoglobin A1c (HbA1c)

    Time frame: Baseline to Week 40

Secondary outcomes

  1. Achievement of HbA1c < 7% (53 mmol/mol)

    Time frame: Week 40

  2. Achievement of HbA1c ≤ 6.5% (48 mmol/mol)

    Time frame: Week 40

  3. Percent change in body weight

    Time frame: Baseline to Week 40

  4. Change from baseline in body weight

    Time frame: Baseline to Week 40

  5. Change from baseline in Systolic Blood Pressure (SBP)

    Time frame: Baseline to Week 40

  6. Achievement of ≥5% weight loss from baseline

    Time frame: Baseline to Week 40

  7. Change from baseline in Diastolic Blood Pressure (DBP)

    Time frame: Baseline to Week 40

  8. Time to initiation of rescue medication over 40 weeks

    Time frame: Baseline to Week 40

07

Study locations

2 of 149 sites recruiting
  • Research Site
    Birmingham, Alabama 35233, United States
    Not yet recruiting
  • Research Site
    Daphne, Alabama 36526, United States
    Not yet recruiting
  • Research Site
    Lomita, California 90717, United States
    Not yet recruiting
  • Research Site
    Los Alamitos, California 90720, United States
    Not yet recruiting
  • Research Site
    San Diego, California 92111, United States
    Suspended

    Not enrolling at this site — choose another above.

  • Research Site
    Walnut Creek, California 94598, United States
    Suspended

    Not enrolling at this site — choose another above.

  • Research Site
    Englewood, Colorado 80110, United States
    Not yet recruiting
  • Research Site
    Bridgeport, Connecticut 06606, United States
    Not yet recruiting
  • Research Site
    Jacksonville, Florida 32256, United States
    Not yet recruiting
  • Research Site
    Orlando, Florida 32801, United States
    Not yet recruiting
  • Research Site
    Conyers, Georgia 30094, United States
    Not yet recruiting
  • Research Site
    Decatur, Georgia 30030, United States
    Not yet recruiting
  • Research Site
    Hinesville, Georgia 31313, United States
    Not yet recruiting
  • Research Site
    El Dorado, Kansas 67042, United States
    Not yet recruiting
  • Research Site
    Newton, Kansas 67114, United States
    Not yet recruiting
  • Research Site
    Lexington, Kentucky 40509, United States
    Not yet recruiting
  • Research Site
    Covington, Louisiana 70433, United States
    Not yet recruiting
  • Research Site
    Bowie, Maryland 20715, United States
    Not yet recruiting
  • Research Site
    Southfield, Michigan 48075, United States
    Not yet recruiting
  • Research Site
    Kansas City, Missouri 64111, United States
    Not yet recruiting
  • Research Site
    St Louis, Missouri 63141, United States
    Not yet recruiting
  • Research Site
    Las Vegas, Nevada 89119, United States
    Not yet recruiting
  • Research Site
    Anderson, South Carolina 29621, United States
    Not yet recruiting
  • Research Site
    Knoxville, Tennessee 37909, United States
    Not yet recruiting
  • Research Site
    Fort Worth, Texas 76135, United States
    Suspended

    Not enrolling at this site — choose another above.

  • Research Site
    Irving, Texas 75061, United States
    Not yet recruiting
  • Research Site
    Renton, Washington 98057, United States
    Not yet recruiting
  • Research Site
    Buenos Aires, C1425AGC, Argentina
    Not yet recruiting
  • Research Site
    CABA, C1120AAC, Argentina
    Not yet recruiting
  • Research Site
    Caba, C1128AAF, Argentina
    Not yet recruiting
  • Research Site
    Ciudad de Buenos Aires, C1094AAD, Argentina
    Not yet recruiting
  • Research Site
    Mar del Plata, B7600GNY, Argentina
    Not yet recruiting
  • Research Site
    San Nicolás, B2900DMH, Argentina
    Not yet recruiting
  • Research Site
    San Vicente, 5006, Argentina
    Not yet recruiting
  • Research Site
    Santa Fe, S3000FWO, Argentina
    Not yet recruiting
  • Research Site
    Baotou, 014030, China
    Not yet recruiting
  • Research Site
    Binzhou, 256606, China
    Not yet recruiting
  • Research Site
    Cangzhou, 061002, China
    Not yet recruiting
  • Research Site
    Changsha, 430033, China
    Not yet recruiting
  • Research Site
    Chengdu, 610081, China
    Not yet recruiting
  • Research Site
    Ganzhou, 341099, China
    Not yet recruiting
  • Research Site
    Haikou, 570208, China
    Not yet recruiting
  • Research Site
    Hangzhou, 310006, China
    Not yet recruiting
  • Research Site
    Huangshi, 435000, China
    Not yet recruiting
  • Research Site
    Huzhou, 313003, China
    Not yet recruiting
  • Research Site
    Jinan, 250013, China
    Not yet recruiting
  • Research Site
    Jinzhou, 121002, China
    Not yet recruiting
  • Research Site
    Lanzhou, 730000, China
    Not yet recruiting
  • Research Site
    Lianyungang, 222023, China
    Not yet recruiting
  • Research Site
    Liaocheng, 252000, China
    Not yet recruiting
  • Research Site
    Liuzhou, 545006, China
    Not yet recruiting
  • Research Site
    Loudi, 417099, China
    Not yet recruiting
  • Research Site
    Luoyang, 471001, China
    Not yet recruiting
  • Research Site
    Luoyang, 471003, China
    Not yet recruiting
  • Research Site
    Nanchang, 330006, China
    Not yet recruiting
  • Research Site
    Nanjing, 2100008, China
    Not yet recruiting
  • Research Site
    Nanjing, 211100, China
    Not yet recruiting
  • Research Site
    Nanyang, 473000, China
    Not yet recruiting
  • Research Site
    Ningbo, 315010, China
    Not yet recruiting
  • Research Site
    Panjin, 124000, China
    Not yet recruiting
  • Research Site
    Qingdao, 266035, China
    Not yet recruiting
  • Research Site
    Sanmenxia, 472000, China
    Not yet recruiting
  • Research Site
    Shanghai, 200040, China
    Not yet recruiting
  • Research Site
    Suining Shi, 629000, China
    Not yet recruiting
  • Research Site
    Tonghua, 134000, China
    Not yet recruiting
  • Research Site
    Xi'an, 710077, China
    Not yet recruiting
  • Research Site
    Xiangtan, 411100, China
    Not yet recruiting
  • Research Site
    Xuancheng, 242000, China
    Not yet recruiting
  • Research Site
    Yibin, 610500, China
    Not yet recruiting
  • Research Site
    Yichang, 443003, China
    Not yet recruiting
  • Research Site
    Yuncheng, 044099, China
    Not yet recruiting
  • Research Site
    Zhengzhou, 450002, China
    Not yet recruiting
  • Research Site
    Zhengzhou, 450012, China
    Not yet recruiting
  • Research Site
    Zhenjiang, 212002, China
    Not yet recruiting
  • Research Site
    Gandrup, 9362, Denmark
    Not yet recruiting
  • Research Site
    Herlev, 2730, Denmark
    Not yet recruiting
  • Research Site
    Hillerød, 3400, Denmark
    Not yet recruiting
  • Research Site
    Hvidovre, 2650, Denmark
    Not yet recruiting
  • Research Site
    Athens, 10676, Greece
    Not yet recruiting
  • Research Site
    Athens, 11526, Greece
    Not yet recruiting
  • Research Site
    Athens, 12131, Greece
    Not yet recruiting
  • Research Site
    Athens, 15125, Greece
    Not yet recruiting
  • Research Site
    Heraklion, 71500, Greece
    Not yet recruiting
  • Research Site
    Piraeus, 18454, Greece
    Not yet recruiting
  • Research Site
    Thessaloniki, 54636, Greece
    Not yet recruiting
  • Research Site
    Thessaloniki, 57001, Greece
    Not yet recruiting
  • Research Site
    Thessaloniki, 57010, Greece
    Not yet recruiting
  • Research Site
    Budapest, 1027, Hungary
    Not yet recruiting
  • Research Site
    Budapest, 1036, Hungary
    Suspended

    Not enrolling at this site — choose another above.

  • Research Site
    Budapest, 1138, Hungary
    Not yet recruiting
  • Research Site
    Debrecen, 4032, Hungary
    Not yet recruiting
  • Research Site
    Dunaújváros, 2400, Hungary
    Not yet recruiting
  • Research Site
    Szeged, 6725, Hungary
    Suspended

    Not enrolling at this site — choose another above.

  • Research Site
    Szolnok, 5000, Hungary
    Suspended

    Not enrolling at this site — choose another above.

  • Research Site
    Amagasaki-shi, 660-8550, Japan
    Not yet recruiting
  • Research Site
    Chiba, 261-0004, Japan
    Not yet recruiting
  • Research Site
    Chitose-shi, 066-0032, Japan
    Not yet recruiting
  • Research Site
    Chūōku, 1040031, Japan
    Not yet recruiting
  • Research Site
    Koga-shi, 306-0232, Japan
    Not yet recruiting
  • Research Site
    Minatoku, 105-0004, Japan
    Not yet recruiting

Showing the first 100 of 149 sites across 13 countries. Choose a country and city above to see the rest.

08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.

Supporting information: Study protocol, Statistical analysis plan

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA PhRMA Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure

Access criteria: When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.

Data sharing details ↗ · vivli.org

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2026 (actual). Primary completion is estimated for Jul 2028, 24 months after the start.

Of 438 industry-sponsored phase 3 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 26. This study's planned 24 months is above that.

Counting every sponsor, half of 525 studies reached it within 20 months; a quarter within 14 and three quarters within 30.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 18, 2026
First posted
Jun 23, 2026
StartActual
Jul 6, 2026
Primary completionEst.
Jul 14, 2028
CompletionEst.
Jul 14, 2028
Last update
Aug 31, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 31, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07662044
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Jun 23, 2026
Start date
Jul 6, 2026
Primary completion
Jul 14, 2028 (estimated)
Completion
Jul 14, 2028 (estimated)
Last update
Aug 31, 2026

Study contacts

AstraZeneca Clinical Study Information Center
Contact
information.center@astrazeneca.com
1-877-240-9479

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Elecoglipron · Dapagliflozin

Start the discussion